RAF1 and colorectal cancer: Similarly, EGFR is overexpressed in 60–80% of colorectal cancers and specific antibody therapies, including cetuximab and panitumumab, have been used against EGFR and to target its downstream RAS/RAF/MEK/ERK signaling pathway [34,35].